Provider: ValuEngine, Inc.
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Innate Pharma SA Announces New Preclinical Data on Lirilumab
Innate Pharma SA announced new preclinical results from research conducted by Dr Holbrook Kohrt from Stanford University, Innate Pharma and CIML1 on Lirilumab. They support the monotherapy activity of lirilumab in mouse models of lymphoma, through the enhancement of NK cell cytotoxicity. Furthermore, the new data showed that in combination with the anti-CD20 antibody rituximab, lirilumab enhanced NK cell-mediated, antibody-dependent cellular cytotoxicity (ADCC) against lymphoma in vitro and in vivo in mouse models. Taken together, these data reinforce the rationale for the development of lirilumab in onco-hematology, and open new perspectives for the combination of lirilumab with antibody drugs active through ADCC.
- Share this
- Digg this